ESTRO 2024 - Abstract Book

S5683

RTT - Patient experience and quality of life

ESTRO 2024

[4] Durrant L, et al. (2023) A new model of care – developing an RTT led regional radiotherapy late effects service. Radiotherapy and Oncology. 182, S443. doi.org/10.1016/S0167-8140(23)08418-9

[5] EQ-5D-5L (2009). Accessible online Euroqol.org

[6] EORTC QLQ-C30 (1995) Version 3. Accessible online eortc/org

[7] Giesinger J, et al. (2020). Threshold for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clinical Epidemiology. 118, 1-8. Doi: 10.1016/j.jclinepi.2019.10.003

[8] Husson O, et al. (2020). The EORTC QLQ-C30 summary score as a prognostic factor for survival of patients with cancer in the “real-world”. Results from the population-based PROFILES registry. The Oncologist 25(4), 722-732

1707

Digital Poster

Patient Reported Outcome Measure (PROM) Selection for a Head and Neck Late Effects Service

Sabina Khan, Danielle Fairweather

University College London Hospital, Radiotherapy/ Proton Beam Therapy/ Oncology, London, United Kingdom

Purpose/Objective:

Head and Neck Cancer (HNC) is the seventh most common cancer globally, and accounts for 660,000 new cancers and 325,000 deaths annually. The combined mortality for HNC cancer has fallen by 11% since the last few decades [1]. There are many potential contributing factors associated with this increase in survival of HNC, but this also means there are more HNC patients surviving longer with late and long-term treatment-related side effects [1,2]. Due to the proximity of disease to critical structures, HNCs and the current treatment strategies such as radiotherapy have many lasting negative consequences on a wide range of vital and social functions such as swallowing, chewing, speech, pain, body and facial disfigurement, as well as psychiatric and emotional distress [2]. As survival rates increase, so does the physically and emotional burden of side effects, and therefore it is important that these are addressed so patients can have lasting and meaningful lives after cancer treatment [2]. At this single centre, HNC patients are a key stakeholder of the radiotherapy and proton beam therapy service, and to support patients’ post-treatment, a business case was launched to instate a HNC late effects clinic. The clinic is Consultant RTT led and the first solely HNC late effects clinic within the UK. As part of this process, a robust way of collecting patient outcomes within the clinic needed to be identified. Patient Reported Outcome Measures (PROMs) are questionnaires which measure a patient’s perspective of their own Health-Related Quality of-Life (HRQoL) and provides health care professionals with actionable data to improve symptom management [3,4]. The aim of this research was to identify a PROM that could be used as screening and monitoring tool, and therefore captures the known HNC late effects as well as HRQoL in this specific cohort of patients.

Material/Methods: